Analysts expect Viewray Inc (NASDAQ:VRAY) to announce ($0.29) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Viewray’s earnings. The highest EPS estimate is ($0.25) and the lowest is ($0.34). Viewray posted earnings of ($0.25) per share in the same quarter last year, which suggests a negative year over year growth rate of 16%. The firm is expected to issue its next earnings report on Thursday, November 14th.
According to Zacks, analysts expect that Viewray will report full-year earnings of ($1.21) per share for the current year, with EPS estimates ranging from ($1.33) to ($1.10). For the next financial year, analysts expect that the company will report earnings of ($0.88) per share, with EPS estimates ranging from ($1.11) to ($0.65). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that that provide coverage for Viewray.
Viewray (NASDAQ:VRAY) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.32) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.09). Viewray had a negative net margin of 128.13% and a negative return on equity of 67.02%. The business had revenue of $30.17 million during the quarter, compared to analysts’ expectations of $25.92 million. During the same quarter in the prior year, the firm earned ($0.30) EPS. Viewray’s revenue for the quarter was up 83.5% on a year-over-year basis.
NASDAQ:VRAY traded up $0.08 during trading hours on Friday, hitting $3.49. 1,573,297 shares of the stock were exchanged, compared to its average volume of 1,620,864. Viewray has a 52-week low of $2.76 and a 52-week high of $10.44. The firm’s fifty day moving average price is $4.47 and its 200 day moving average price is $7.38. The company has a current ratio of 4.01, a quick ratio of 3.01 and a debt-to-equity ratio of 0.55. The company has a market cap of $335.82 million, a P/E ratio of -3.56 and a beta of 1.06.
In other news, insider James F. Dempsey sold 279,414 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $3.57, for a total transaction of $997,507.98. Following the transaction, the insider now directly owns 272,433 shares in the company, valued at approximately $972,585.81. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Scott William Drake bought 131,260 shares of the stock in a transaction dated Tuesday, August 13th. The shares were bought at an average price of $3.81 per share, for a total transaction of $500,100.60. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 306,175 shares of company stock valued at $1,235,805. 15.48% of the stock is owned by company insiders.
Several institutional investors have recently modified their holdings of VRAY. BNP Paribas Arbitrage SA boosted its holdings in shares of Viewray by 57,004.3% during the 1st quarter. BNP Paribas Arbitrage SA now owns 13,134 shares of the company’s stock worth $97,000 after purchasing an additional 13,111 shares during the last quarter. Stephens Inc. AR acquired a new position in shares of Viewray during the 1st quarter worth approximately $117,000. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Viewray by 4.3% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 74,440 shares of the company’s stock worth $550,000 after purchasing an additional 3,090 shares during the last quarter. TD Asset Management Inc. boosted its holdings in shares of Viewray by 4.3% during the 1st quarter. TD Asset Management Inc. now owns 60,167 shares of the company’s stock worth $445,000 after purchasing an additional 2,500 shares during the last quarter. Finally, Royce & Associates LP boosted its holdings in shares of Viewray by 7.8% during the 1st quarter. Royce & Associates LP now owns 498,900 shares of the company’s stock worth $3,687,000 after purchasing an additional 35,900 shares during the last quarter.
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Featured Story: What are different types of coverage ratios?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.